NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis → How Biden has already won 2024 (From Porter & Company) (Ad) Free GERN Stock Alerts $4.59 +0.70 (+17.99%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$4.45▼$5.1550-Day Range$3.10▼$4.5952-Week Range$1.64▼$5.15Volume98.94 million shsAverage Volume11.31 million shsMarket Capitalization$2.72 billionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Geron alerts: Email Address Geron MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside41.6% Upside$6.50 Price TargetShort InterestBearish9.09% of Shares Sold ShortDividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.73Based on 22 Articles This WeekInsider TradingSelling Shares$2.40 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.35) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 starsMedical Sector205th out of 903 stocksPharmaceutical Preparations Industry90th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeron has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Geron's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.09% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Geron has recently increased by 2.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -35.24% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -2.80. Previous Next 3.2 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Geron this week, compared to 4 articles on an average week.Search Interest39 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.MarketBeat Follows19 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 12% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,400,000.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -13.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -13.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 9.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesJune 7 at 12:57 PM | marketbeat.comGeron Corporation: FDA Approval Fuels Stock Price SurgeThe recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement marks a turning point for Geron and underscores the company's commitment to developing innovative therapies for complex diseases.June 7 at 12:56 PM | marketbeat.comGeron Corporation: FDA Approval Fuels Stock Price SurgeFDA approval paves the way for Geron Corporation's rise as a leader in hematologic malignancy treatments.June 6, 2024 | insidertrades.comInsider Selling: Geron Co. (NASDAQ:GERN) CEO Sells 600,000 Shares of StockJune 9 at 4:08 AM | americanbankingnews.comGeron (NASDAQ:GERN) PT Raised to $6.00June 9 at 2:20 AM | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Geron (NASDAQ:GERN)June 8 at 8:00 AM | seekingalpha.comGeron: Innovative Rytelo Enters A Challenging MDS MarketJune 8 at 6:37 AM | fool.comIs Geron Stock a Buy Following Its First New Drug Approval?June 8 at 2:02 AM | americanbankingnews.comGeron (NASDAQ:GERN) Reaches New 1-Year High on Analyst UpgradeJune 8 at 1:24 AM | americanbankingnews.comGeron Target of Unusually Large Options Trading (NASDAQ:GERN)June 7 at 4:10 PM | investopedia.comGeron Stock Soars on FDA Approval of Drug for Patients With Rare Blood CancersJune 7 at 11:02 AM | investorplace.comWhy Is Geron (GERN) Stock Up 18% Today?June 7 at 10:01 AM | investing.comGeron surges after winning first US FDA approval for blood disorder drugJune 7 at 12:01 AM | seekingalpha.comGeron lead asset approved in the U.S. for blood cancerJune 6, 2024 | businesswire.comGeron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaJune 2, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Stock Price Up 5.2%May 23, 2024 | seekingalpha.comGeron Corporation: A High-Risk Deal With A Good Chance Of SuccessMay 16, 2024 | businesswire.comGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | finance.yahoo.comGeron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipating Imetelstat’s Approval and Market PotentialMay 3, 2024 | finance.yahoo.comGeron Corp (GERN) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves and Financial HealthMay 3, 2024 | finance.yahoo.comThis Is Why Geron Corporation's (NASDAQ:GERN) CEO Compensation Looks AppropriateMay 3, 2024 | finance.yahoo.comQ1 2024 Geron Corp Earnings CallMay 3, 2024 | fool.comGeron (GERN) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Geron Amid Positive Imetelstat Launch Prospects and Strong FinancialsMay 2, 2024 | markets.businessinsider.comGeron Corporation Q1 Loss increases, but beats estimatesSee More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/09/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+41.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-38,730.00% Pretax Margin-38,729.81% Return on Equity-68.16% Return on Assets-47.26% Debt Debt-to-Equity Ratio0.03 Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$240,000.00 Price / Sales11,343.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book9.98Miscellaneous Outstanding Shares593,130,000Free Float574,746,000Market Cap$2.72 billion OptionableOptionable Beta0.43 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 73)Chairman of the Board, President & CEO Comp: $1.36MMs. Michelle J. Robertson (Age 57)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Comp: $340.98kDr. Andrew J. Grethlein Ph.D. (Age 60)Executive VP & COO Comp: $827.01kMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMs. Shannon Odam (Age 49)Senior VP & Chief People Officer Ms. Melissa A. Kelly Behrs (Age 60)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 54)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 62)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsChinook TherapeuticsNASDAQ:KDNYOrganogenesisNASDAQ:ORGOInozyme PharmaNASDAQ:INZYFoghorn TherapeuticsNASDAQ:FHTXZIOPHARM OncologyNASDAQ:ZIOPView All CompetitorsInsiders & InstitutionsJohn A ScarlettSold 600,000 sharesTotal: $2.40 M ($4.00/share)Teachers Retirement System of The State of KentuckyBought 58,787 shares on 5/28/2024Ownership: 0.051%Farallon Capital Management LLCBought 7,495,000 shares on 5/24/2024Ownership: 1.264%Artal Group S.A.Bought 1,281,194 shares on 5/17/2024Ownership: 0.216%Kennedy Capital Management LLCSold 9,915 shares on 5/16/2024Ownership: 0.190%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions Should I buy or sell Geron stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price target for 2024? 5 brokers have issued 1-year target prices for Geron's shares. Their GERN share price targets range from $4.50 to $10.00. On average, they anticipate the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2024? Geron's stock was trading at $2.11 at the start of the year. Since then, GERN stock has increased by 117.5% and is now trading at $4.59. View the best growth stocks for 2024 here. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $0.30 million during the quarter, compared to analyst estimates of $0.15 million. Geron had a negative net margin of 38,730.00% and a negative trailing twelve-month return on equity of 68.16%. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Loncar China Biopharma ETF (CHNA), Range Cancer Therapeutics ETF (CNCR), WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). Who are Geron's major shareholders? Geron's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.04%), Vivo Capital LLC (4.98%), NEA Management Company LLC (2.15%), Farallon Capital Management LLC (1.26%), Affinity Asset Advisors LLC (0.42%) and Price T Rowe Associates Inc. MD (0.35%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GERN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.